Farallon Capital Management LLC Raises Position in uniQure N.V. $QURE

Farallon Capital Management LLC lifted its stake in uniQure N.V. (NASDAQ:QURE) by 3,935.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 565,000 shares of the biotechnology company’s stock after purchasing an additional 551,000 shares during the period. Farallon Capital Management LLC owned 0.91% of uniQure worth $32,979,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Swiss National Bank bought a new position in shares of uniQure during the second quarter valued at approximately $1,080,000. Sanders Morris Harris LLC bought a new stake in shares of uniQure during the 3rd quarter worth approximately $5,081,000. Vanguard Group Inc. boosted its holdings in uniQure by 15.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after acquiring an additional 152,417 shares during the period. Aberdeen Group plc boosted its holdings in uniQure by 6.9% during the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock valued at $171,593,000 after acquiring an additional 189,029 shares during the period. Finally, JPMorgan Chase & Co. grew its position in uniQure by 471.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after acquiring an additional 1,491,486 shares during the last quarter. 78.83% of the stock is owned by institutional investors.

Insider Transactions at uniQure

In other uniQure news, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total transaction of $174,319.20. Following the sale, the director owned 20,439 shares in the company, valued at approximately $557,575.92. The trade was a 23.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 14,581 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $132,103.86. Following the completion of the transaction, the chief executive officer directly owned 660,658 shares in the company, valued at $5,985,561.48. This represents a 2.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 81,399 shares of company stock worth $1,527,645 over the last 90 days. Insiders own 4.79% of the company’s stock.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and maintained a $70 price target on QURE, giving some institutional-support context despite lowered estimates. HC Wainwright Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE)
• Neutral Sentiment: Market/opinion coverage is running — e.g., a Seeking Alpha piece frames uniQure’s situation as complex and worth reading for background, but it does not add new regulatory facts. A Unique Situation For UniQure
• Negative Sentiment: FDA reportedly issued an unprecedented public rebuke alleging uniQure pushed “distorted” or “manipulated” data related to AMT‑130; plaintiffs’ firms are citing that as the basis to expand securities investigations — a major regulatory risk for the company’s lead program and valuation. QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data …
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs in securities class actions (class period: Sept. 24–Oct. 31, 2025) and have set an April 13, 2026 lead‑plaintiff filing deadline — increasing legal and settlement-tail risk. Representative filings/alerts include Kessler Topaz, Pomerantz and Schall. uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz … QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit …
• Negative Sentiment: HC Wainwright materially cut near‑ and long‑term EPS forecasts (Q1–Q4 2026 and FY2026–FY2030), reducing future earnings visibility and implying a slower timeline to commercialization/profitability despite the Buy rating. That revision increases downside risk to current valuation. uniQure (NASDAQ: QURE) analyst/estimate coverage — MarketBeat

uniQure Price Performance

Shares of QURE stock opened at $15.53 on Monday. The stock’s 50-day moving average is $21.37 and its 200 day moving average is $29.68. uniQure N.V. has a 1-year low of $7.76 and a 1-year high of $71.50. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. The company has a market cap of $971.09 million, a P/E ratio of -4.50 and a beta of 0.73.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The firm had revenue of $5.57 million during the quarter, compared to analyst estimates of $4.84 million. Research analysts predict that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on QURE shares. Leerink Partners reiterated an “outperform” rating and set a $35.00 target price on shares of uniQure in a research report on Monday, March 2nd. Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $12.00 to $35.00 in a research note on Wednesday, March 11th. The Goldman Sachs Group decreased their price objective on shares of uniQure from $37.00 to $9.00 and set a “neutral” rating for the company in a report on Tuesday, March 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Finally, Wolfe Research started coverage on shares of uniQure in a research report on Monday, February 23rd. They set a “peer perform” rating on the stock. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.